Experimental cancer vaccine to enter clinical trials in 2027
Promomed has revealed its intention to begin first-stage clinical testing of an experimental peptide cancer vaccine in 2027 following the completion of preclinical studies conducted in collaboration with international partners.
According to Kira Zaslavskaya, the company's Director of New Products, the vaccine has been designed as a multivalent, multi-target therapeutic platform capable of addressing various forms of cancer.
She noted that the candidate differs from messenger RNA (mRNA) vaccines, relying instead on peptide-based technology to stimulate anti-tumor immune responses.
Zaslavskaya explained that the clinical trials will be conducted directly on cancer patients, as oncology therapeutics of this type are generally not tested on healthy volunteers.
How Does a Peptide Cancer Vaccine Work?
Peptide cancer vaccines function by introducing short protein fragments derived from cancer cells into the immune system. These fragments help the body recognize tumor-specific markers, enabling immune cells to identify and attack malignant tissues more effectively.
Unlike mRNA vaccines, which deliver genetic instructions for temporary protein production inside cells, peptide vaccines provide ready-made protein components that directly stimulate the immune system to mount a targeted response against tumors.
About Promomed
Promomed is a Russian biopharmaceutical company with an integrated research and development infrastructure. The company operates its own R&D center as well as the Biokhimik and Pirakhim manufacturing facilities, and maintains a portfolio of more than 370 pharmaceutical products across multiple therapeutic areas.
